Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Expenses (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Operating Expenses for 3 consecutive years, with $10.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 10.01% to $10.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.7 million, a 17.7% increase, with the full-year FY2024 number at $47.4 million, up 32.15% from a year prior.
  • Operating Expenses was $10.3 million for Q3 2025 at Mereo BioPharma, down from $10.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $15.3 million in Q4 2024 to a low of $6.4 million in Q2 2023.
  • A 3-year average of $10.5 million and a median of $10.3 million in 2025 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 100.81% in 2024; the steepest drop was 15.79% in 2024.
  • Mereo BioPharma's Operating Expenses stood at $8.4 million in 2023, then skyrocketed by 81.82% to $15.3 million in 2024, then plummeted by 32.47% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Operating Expenses are $10.3 million (Q3 2025), $10.9 million (Q2 2025), and $11.2 million (Q1 2025).